A Phase 1 interventional study of bilastine and Bilastine in Healthy, sponsored by Faes Farma, S.A.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-04-05.
Sponsored by Faes Farma, S.A. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.
Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 80th largest by enrollment of the 119 interventional ones that give a count, is one of 10 that started in 2006, is one of 19 in phase 1, and was the 23rd registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Polyrizon Ltd. · Sites in United States
Ages 18–75
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–100
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18–60 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 4–100 · Healthy volunteers
QHSLab, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 23 · Phase 3 35 · Phase 4 25
First in 1996; this study’s year is marked. 10 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 54 across the 119 interventional studies, 60 across the 21 observational. Of the 122 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 141 have an industry lead sponsor. The 10 most frequent:
Faes Farma, S.A. is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
Faes Farma, S.A. has 4 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
3 of the studies in Rhinitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06623799QHSLab, Inc.Impact of Help-Seeking Behaviors on Allergic Rhinitis and Mental Health: A Longitudinal Study | 2027-01-25 |
| NCT05331170The University of Texas Medical Branch, GalvestonViral Mucosal Reprogramming | 2027-05-01 |
| NCT07588672Polyrizon Ltd.Evaluation of the Efficacy, Safety, and Tolerability of PL-14 Allergy Blocker Compared to Saline Spray in Patients With Seasonal Allergic Rhinitis | 2027-07-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 141 studies in Rhinitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of two doses of bilastine (20 and 100 mg) compared to bilastine 20 mg administered with ketoconazole 400 mg, moxifloxacin 400 mg, and placebo. Subjects will receive each of the five study treatments in a crossover fashion administered once daily for 4 days.
This is a single center, Phase 1 study that utilizes a randomized, multiple-dose, double-blind, 5-way crossover design with a placebo control and two active controls. A minimum seven day washout period following four days of dosing for each of the five treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilastine 20 mg
Drug: bilastine
Bilastine 100 mg
Drug: Bilastine
Bilastine 20 mg + Ketoconazole 400 mg
Drug: Bilastine & Ketoconazole
Moxifloxacin 400 mg
Drug: Moxifloxacin
Placebo
Drug: Placebo
20 mg tablets.
100 mg (5 tablets of 20 mg)
Drug pages: Bilastine · Ketoconazole
1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
1 capsule containing moxifloxacin 400 mg tablet
Placebo tablets
QTc Interval prolongation
Time frame: 4 days
vital signs, adverse events, and routine clinical laboratory tests
Time frame: 4 days
The record gives a start of Aug 2006, a primary completion of Dec 2006 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bilastine
Faes Farma, S.A.